fashion -WSS

fashion

author：knowledge 2025-10-01 23:05:29 - browse：448

Sammy Kimball for STAT

Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT’s Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

For more on what we cover, here’s the story on conflicts of interest; here’s the latest on RSV vaccines; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Merck drug for rare lung condition set for approval in U.S.

knowledge

WSS

Steward Health Care has deal to sell doctor network to UnitedHealth

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

FDA's naming rule on biosimilars has undermined competition

STAT Summit: The economic case for universal basic health care

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Merck drug for rare lung condition set for approval in U.S.

Wikipedia

fashion

hotspot

Apple is now the first public company to be valued at $3 trillion

J&J lung cancer data amount to new salvo against AstraZeneca

Novavax promises a turnaround & Lilly roils the obesity market

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Moonlake's readout produced a cash windfall. Risks remain

Steward Health Care has deal to sell doctor network to UnitedHealth

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA's naming rule on biosimilars has undermined competition

focus

Oprah kicked off a national conversation on obesity. Let's have it

The Readout: Lenmeldy, GLP

Why the world’s most expensive drug might be worth the price

Patient advocates debate FDA's accelerated approval process

UnitedHealth, Optum discontinue NaviHealth name

FDA clears Verve to begin U.S. study of gene

knowledge

entertainment

hotspot

knowledge